BioNTech SE Expected to Post Q3 2024 Earnings of $0.86 Per Share (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) – HC Wainwright raised their Q3 2024 earnings estimates for shares of BioNTech in a research note issued on Tuesday, August 27th. HC Wainwright analyst R. Burns now expects that the company will post earnings of $0.86 per share for the quarter, up from their previous forecast of $0.85. HC Wainwright currently has a “Buy” rating and a $113.00 target price on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($2.04) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2024 earnings at $0.63 EPS, Q3 2025 earnings at $0.83 EPS and Q4 2025 earnings at $0.80 EPS.

BNTX has been the topic of a number of other reports. BMO Capital Markets lowered their price target on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. TD Cowen dropped their price target on BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. JPMorgan Chase & Co. cut their price target on BioNTech from $94.00 to $91.00 and set an “underweight” rating for the company in a report on Thursday, August 15th. Deutsche Bank Aktiengesellschaft raised BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a research note on Wednesday, August 7th. Finally, HSBC raised BioNTech from a “hold” rating to a “buy” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and a consensus target price of $109.09.

BioNTech Trading Up 1.3 %

Shares of BNTX opened at $88.20 on Wednesday. BioNTech has a 52-week low of $76.53 and a 52-week high of $125.83. The stock has a market cap of $20.97 billion, a PE ratio of 176.40 and a beta of 0.23. The firm’s fifty day moving average is $83.92 and its two-hundred day moving average is $89.39. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The company had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The firm’s revenue for the quarter was down 23.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.86) EPS.

Hedge Funds Weigh In On BioNTech

Hedge funds have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd grew its stake in shares of BioNTech by 2.5% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock valued at $492,000 after buying an additional 116 shares in the last quarter. Covestor Ltd grew its position in BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after acquiring an additional 133 shares in the last quarter. GAMMA Investing LLC increased its stake in BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the period. Arlington Capital Management Inc. lifted its position in shares of BioNTech by 10.0% during the first quarter. Arlington Capital Management Inc. now owns 2,200 shares of the company’s stock worth $203,000 after purchasing an additional 200 shares in the last quarter. Finally, Midwest Professional Planners LTD. boosted its stake in shares of BioNTech by 7.2% in the first quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after purchasing an additional 212 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.